We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Near Real-Time Osteoporosis and Bone Cancer Test Developed

By LabMedica International staff writers
Posted on 30 Aug 2015
Image: Photomicrograph demonstrating typical multiple myeloma histology, with monoclonal proliferation of plasma cells (Photo courtesy of Ohio State University College of Medicine).
Image: Photomicrograph demonstrating typical multiple myeloma histology, with monoclonal proliferation of plasma cells (Photo courtesy of Ohio State University College of Medicine).
A new test which measures changes in calcium isotope ratios offers the possibility of near real time monitoring of bone diseases, such as osteoporosis and multiple myeloma.

Bones are largely built of calcium, and the turnover of calcium can indicate the development of bone diseases such as osteoporosis and the cancer multiple myeloma and using techniques developed by geochemists it was found possible to apply them to a new, rapid test of bone health.

Scientists at Arizona State University (Tempe, AZ, USA) worked with the US National Aeronautics and Space Administration (NASA, Washington DC, USA) and measured calcium isotope ratios in urine from 30 shuttle astronauts, before, during, and after the flights. This allowed them to confirm that the test worked at high sensitivity. They also looked at a group of 71 patients who either had multiple myeloma (bone cancer), or were at risk of multiple myeloma.

The methodology used mass spectrometry and can discern the relative ratios of the calcium isotopes 42Ca and 44Ca in bone. The researchers found that lighter calcium isotopes, such as 42Ca, are absorbed from the blood into the bone during bone formation. Conversely, these light isotopes tend to be released into the bloodstream when bones break down. By measuring the ratios of the two isotopes in blood or urine scientists can calculate the rate of change of bone mass.

Ariel Anbar, PhD, the lead scientists of the study said, “What we saw with cancer patients was interesting. Those patients who tended to lose the lighter 42Ca isotope seemed to be the ones where the cancer was the most active. This means that the tests could theoretically feed into decisions on whether or not to treat a patient, for example if a cancer was dormant or growing very slowly, and to assess the effectiveness of treatments. The advantage for this methodology is that the patient doesn't have to come to the machine; the measurements can be done with a blood or urine test.”

Related Links:

Arizona State University
US National Aeronautics and Space Administration


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Pipette Calibration System
Artel PCS®
POC Immunoassay Analyzer
Procise DX

Channels

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more